Vimarsana
Biggest News Aggregation in the World

Page 46 - Eppendorf News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eppendorf. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eppendorf Today - Breaking & Trending Today

Early rhythm control strategy for AF may be cost-effective - Vimarsana News

Early rhythm control strategy for AF may be cost-effective

An early rhythm control strategy for treatment of atrial fibrillation was cost-effective in a German population, according to new data from the EAST-AFNET 4 trial.“The health benefit of early rhythm control is evident. However, the cost-effectiveness of the new treatment strategy has not been evaluated so far,” Sophie Gottschalk, MSc, research fellow and PhD student in the department

Source: healio.com
Brain Stimulation Can Improve Prognosis Following a Stroke - Vimarsana News

Brain Stimulation Can Improve Prognosis Following a Stroke

New approaches based on activation or inhibition of brain networks should optimize the therapy of neurological and psychiatric diseases in the future.

Biotech Hub Launches In Glendale - San Fernando Valley Business Journal - Vimarsana News

Biotech Hub Launches In Glendale - San Fernando Valley Business Journal

Lab digitization servicehas German, Armenian links.

Source: sfvbj.com
Industrial Microbiology Market Forecast 2022-2027: Growth Factor and Current Demand and Top Growing Companies | Thermo Fisher Scientific Inc., and SSI Diagnostica | - Vimarsana News

Industrial Microbiology Market Forecast 2022-2027: Growth Factor and Current Demand and Top Growing Companies | Thermo Fisher Scientific Inc., and SSI Diagnostica |

A research report by MarkNtel Advisors on the Industrial Microbiology Market brings together an in-depth understanding of the industry exhibiting all the

Is Early Rhythm Control in Atrial Fibrillation Care Cost-effective? - Vimarsana News

Is Early Rhythm Control in Atrial Fibrillation Care Cost-effective?

An analysis based on the EAST – AFNET 4 trial